Apellis Pharmaceuticals Provides Update on Its Phase 3 Program for Patients with Geographic Atrophy

- December 20th, 2018

Apellis Pharmaceuticals (Nasdaq:APLS) today provided an update on the status of its Phase 3 program for APL-2 in patients with Geographic Atrophy (GA). Apellis expects to be able to restart enrollment of its two Phase 3 GA trials (DERBY & OAKS) in Q2 2019 and to have fully enrolled both studies by the end of Q1 … Continued

Apellis Pharmaceuticals (Nasdaq:APLS) today provided an update on the status of its Phase 3 program for APL-2 in patients with Geographic Atrophy (GA). Apellis expects to be able to restart enrollment of its two Phase 3 GA trials (DERBY & OAKS) in Q2 2019 and to have fully enrolled both studies by the end of Q1 2020, within the originally planned timeline for completion.

As quoted in the press release:

As previously disclosed, the Company voluntarily implemented a temporary pause in dosing in the DERBY and OAKS Phase 3 trials due to observed cases of non-infectious inflammation in patients treated from a single manufacturing lot of APL-2 intravitreal drug product. The Company believes the source of inflammation in the Phase 3 trials resides in an impurity or contaminant in the active pharmaceutical ingredient (API). Inflammation in all affected patients has resolved. In the Phase 2 FILLY trial, where more than 1,500 intravitreal injections of APL-2 were given, APL-2 was well-tolerated with only a single case of non-infectious inflammation reported. The source of inflammation has had no known impact on the studies utilizing systemic administration of APL-2.

Based on Apellis’ investigation, which included a full manufacturing process review, six non-clinical studies in two species and an ongoing Phase 1b clinical study in patients with GA with low vision, the Company does not believe that the following were the root causes for the observed inflammation in the Phase 3 GA program: (i) The pharmacology or chemical composition of APL-2, (ii) A formulation change that was implemented between the Phase 2 FILLY trial and the Phase 3 trials, and (iii) The fill and finish process for the APL-2 intravitreal drug product.

Click here to read the full press release.

Find out what experts are saying about the future of cannabis

 
Read our new report today
 

Leave a Reply

Your email address will not be published. Required fields are marked *